Corporate Presentation

September 2021

Disclaimer

Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward-looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

2

Poxel's Investment Highlights

To discover, develop and commercialize innovative therapies for patients suffering from serious chronic and rare diseases with underlying metabolic pathophysiology

acetyl CoA

METABOLIC INFLAMMATION

DISORDERS

(cellular energy

homeostasisTISSUE

imbalances) DEGENERATION & CELL DEATH

apoptosis,

necrosis

3

  • TWYMEEG® (Imeglimin) approved and launched for Type 2 Diabetes in Japan
  • Strategic focus on rare metabolic Indications and NASH
  • Clinical Stage Pipeline with Global Operations
  • Highly Experienced Management Team in Metabolic Diseases

Robust Mid-to-Late Stage Metabolic Pipeline

Focus on Rare Metabolic Diseases and NASH

Indication

MOA

Discovery

PH 1

PH 2 PH 3

Approved/

Partner/ Rights

Upcoming Milestones

/PC

Marketed

Type 2 Diabetes (T2D)

TWYMEEG®

MRC

• TWYMEEG approved for T2D in Japan on

T2D

June 23, 2021

Japan / Asia1

Modulator

• Product launch September 16, 2021

Imeglimin

T2D with

MRC

• Exploring options to move the program forward

US / EU /

CKD stages

Modulator

into Phase 3

Other

3b/4

NASH

PXL065

NASH

Non-Genomic

• Phase 2 results expected Q3 2022

TZD2

505(b)(2) pathway

PXL770

NASH

AMPK3

• Successful Phase 2a Study

Activator

• Evaluate next steps by year end 2022

Rare Metabolic Indications

PXL770

ALD4

AMPK

Activator

PXL065

ALD4

Non-Genomic

TZD

Next-Gen

Not

AMPK

AMPK

Disclosed

Activator

Next-Gen

Not

Non-Genomic

D-TZD

Disclosed

TZD

  • Initiate Phase 2a Q1 2022
  • Initiate Phase 2a Q1 2022
  • Complete PC studies in 2021
  • Select lead candidate(s)

1. Includes: China, South Korea, Taiwan, Indonesia, Vietnam, Thailand, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos. 2. Deuterium-modified thiazolidinediione. 3. AMP-kinase. 4. X-linkedAdrenoLeukoDystrophy.

4

A New Chapter to Drive Shareholder Value

Focus on Rare Metabolic Diseases and NASH

Rare

ALD*

Metabolic

Diseases

PXL065

Type 2 Diabetes

TWYMEEG® (Imeglimin)

NASH D-TZD2 Platform

PXL770

AMPK3 Platform

Partnered in Asia1

with diabetes market

leader in Japan

  • Recent cash infusion of EUR~26.7 million triggered by Japan approval
  • Japan Launch Sept 2021
  • Potential sales-based payments & royalties
  • Phase 2 biopsy data for PXL065 expected in Q3 2022
  • Next Steps for PXL770 pending evaluation YE 2022

External

Opportunities

  • Phase 2a Biomarker POC studies in ALD for 065 & 770; results anticipated YE 2022
  • Pipeline expansion into new indications

1. Japan plus: China, South Korea, Taiwan, Indonesia, Vietnam, Thailand, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos.

5

  1. Deuterium-modifiedthiazolidinediones.
  2. AMP-kinase(allosteric activators) /

* X-linked adrenoleukodystrophy (ALD).

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Poxel SA published this content on 24 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 September 2021 15:41:04 UTC.